Biotech Values

[DewDiligence]

ELEV—(-58%)—reports “promising” phase-1 for EO-3021, a Claudin18.2 ADC:

https://investors.elevationoncology.com/2024-08-06-Elevation-Oncology-Announces-Promising-Initial-Data-from-Phase-1-Clinical-Trial-Evaluating-EO-3021-in-Patients-with-Advanced-Unresectable-or-Metastatic-Solid-Tumors-Likely-to-Express-Claudin-18-2

ORR in the full dataset was 20% (3/15), which is considerably than the ORR from a prior trial in China. (All three PRs came from the n=7 subset of patients whose tumors had high Claudin 18.2 expression.)

ELEV is down 94% from its 2021 IPO (#msg-164599586).